Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Thomas Evers"'
Autor:
Suguru Okami, Coralie Lecomte, Hanaya Raad, Mireia Aguila, Zuzana Mohrova, Makiko Takeichi, Takanori Tsuchiya, Christoph Ohlmeier, Thomas Evers, Alexander Michel
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/9ddc954b6f9843e286264c3e5a036b6a
Autor:
Suguru Okami, Coralie Lecomte, Hanaya Raad, Mireia Aguila, Zuzana Mohrova, Makiko Takeichi, Takanori Tsuchiya, Christoph Ohlmeier, Thomas Evers, Alexander Michel
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Currently, the utilization patterns of medications for heart failure (HF) after worsening HF events remain unelucidated in Japan. Here, we conducted a retrospective cohort study evaluating the changes in HF drug utilization patterns in 6 mon
Externí odkaz:
https://doaj.org/article/1f48edb5644c452b965d76e3a9231df1
Publikováno v:
Drugs - Real World Outcomes, Vol 7, Iss 3, Pp 221-227 (2020)
Abstract Introduction For a new drug to be developed, the desired properties are described in a target product profile. Objective We propose a framework for using real-world data to measure the disease-specific costs of the current standard of care a
Externí odkaz:
https://doaj.org/article/0e95d10e90a84a2099e661056a94add0
Autor:
Richard Sheer, Radhika Nair, Margaret K. Pasquale, Thomas Evers, Meghan Cockrell, Alain Gay, Rakesh Singh, Niklas Schmedt
Publikováno v:
Journal of Primary Care & Community Health, Vol 13 (2022)
Introduction/Objective: Predictive risk models identifying patients at high risk for specific outcomes may provide valuable insights to providers and payers regarding points of intervention and modifiable factors. The goal of our study was to build p
Externí odkaz:
https://doaj.org/article/ad63ed6a0af04f59b28d4bd8bb1aa408
Autor:
Carlos Rubio-Terrés, Ruth Graefenhain de Codes, Darío Rubio-Rodríguez, Thomas Evers, Santiago Grau Cerrato
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 4, Iss 1 (2016)
**Objective:** The aim of this study was to evaluate, from the Spanish National Health System perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial
Externí odkaz:
https://doaj.org/article/80d544f46da04ba298ae1b9a851cc84b
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157769 (2016)
A retrospective cohort analysis of the US MarketScan claims databases was performed to compare persistence and discontinuation rates between the vitamin K antagonist warfarin and the non-vitamin K antagonist oral anticoagulants rivaroxaban and dabiga
Externí odkaz:
https://doaj.org/article/980d3f7c75dc46e8a2d42fd851fabf3d
Publikováno v:
Gaceta Sanitaria, Vol 21, Iss 2, Pp 97-104 (2007)
Objetivos: Evaluar el coste-efectividad de la adición de acarbosa al tratamiento de pacientes con diabetes mellitus tipo 2 (DM2) en España. Métodos: Se utilizó el CORE Diabetes Model (modelo de simulación informática publicado y validado) para
Externí odkaz:
https://doaj.org/article/93530f76465b4fe19f09f84bb24f500c
Autor:
Vishal N. Rao, Derek D. Cyr, Lisa M. Wruck, Gretchen Sanders, Paul Hofmann, Lothar Rössig, Harald Siedentop, Thomas Evers, Michaela Meyer, Karen Paraschin, Richard Nkulikiyinka, Kishan Parikh, G. Michael Felker
Publikováno v:
American Heart Journal. 263:1-14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6ea74e8fe1fd247e5d8a7ba2b641570
https://doi.org/10.1016/j.ahj.2023.04.013
https://doi.org/10.1016/j.ahj.2023.04.013
Publikováno v:
Patient Preference and Adherence. 17:1181-1196
Chi Nguyen,1 Luke Bamber,2 Vincent J Willey,1 Thomas Evers,2 Thomas P Power,3 Judith J Stephenson1 1HealthCore, Inc., Wilmington, DE, USA; 2Bayer AG, Wuppertal, 42096, Germany; 3AIM Specialty Health, Chicago, IL, USACorrespondence: Chi Nguyen, Health
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::904373f9ebf5b81484868133c43bf80c
https://doi.org/10.2147/ppa.s395242
https://doi.org/10.2147/ppa.s395242
Autor:
RICHARD SHEER, RADHIKA NAIR, MARGARET K. PASQUALE, THOMAS EVERS, MEGHAN M. COCKRELL, ALAIN GAY, RAKESH SINGH, NIKLAS SCHMEDT
Publikováno v:
Diabetes. 71
Progression of chronic kidney disease (CKD) is associated with increased risk of cardiovascular or renal events that contribute to increasing healthcare costs. The purpose of this study was to develop predictive models for rapid progression of CKD, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f40d44cfb9f16b14026459a50cc1b856
https://doi.org/10.2337/db22-401-p
https://doi.org/10.2337/db22-401-p